Effect of Lactobacillus Paracasei LC19 on Type 2 Diabetes

Efficacy of Lactobacillus Paracasei LC19 on Newly Diagnosed Type 2 Diabetes

This study is testing if a probiotic called Lactobacillus paracasei LC19 can help lower blood sugar levels in people who have just been diagnosed with Type 2 Diabetes.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Beijing Chao Yang Hospital (other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06639425 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the efficacy of Lactobacillus paracasei LC19 supplementation in lowering glucose levels in patients with newly diagnosed Type 2 Diabetes (T2D). Approximately 60 drug-naive participants will be recruited and randomly assigned to receive either the probiotic or a placebo for a 12-week double-blind treatment period. Laboratory evaluations will confirm eligibility, and participants will be monitored throughout the study to assess the impact of the intervention on their glucose levels.

Who should consider this trial

Good fit: Ideal candidates are drug-naive adults aged 18-65 with newly diagnosed Type 2 Diabetes and specific HbA1c levels.

Not a fit: Patients with other types of diabetes or significant cardiovascular diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a novel dietary intervention for managing glucose levels in patients with Type 2 Diabetes.

How similar studies have performed: While the use of probiotics in diabetes management is an emerging field, this specific approach with Lactobacillus paracasei LC19 is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

* Age 18-65 years, both genders eligible
* Drug-naive patients with newly diagnosed type 2 diabetes
* Subjects with screening HbA1c ≥ 7.0% and ≤ 9.0%
* Subjects understand the nature, significance, potential benefits, inconvenience, and risks and procedure of the study, and voluntarily sign the informed consent form

Exclusion Criteria:

* Other types of diabetes except T2D: type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes, or secondary diabetes (such as acromegaly or Cushing\'s syndrome, etc.)
* Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 6 months
* Subjects with history of hypoglycemia in the past 6 months
* Subjects with history of New York Heart Association class (NYHA) grade of heart function ≥ III or serious cardiovascular diseases (myocardial infarction, or with the history of cardiac interventional therapy or stent implantation, valve disease or valve repair, unstable angina, transient ischemic attack or stroke) within 6 months before the screening period
* Subjects with history of chronic active hepatitis and/or severe liver dysfunction, renal dysfunction, and thyroid dysfunction
* Subjects with a medical history of malignant tumor
* Subjects with history of gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active gastrointestinal ulcers, acute cholecystitis, etc.) or with a history of intestinal resection or other gastrointestinal surgery (such as cholecystectomy) within one year before the screening period
* Subjects with history of surgery, or severe trauma in the past 6 months, or planning to undergo surgery during the study period
* Subjects suffering from severe infections, severe anemia, or neutropenia
* Subjects pregnant or in lactation, or those planning to become pregnant or impregnate during or within 3 months after the study period
* Subjects with history of receiving immunosuppressants, steroids, anti diarrheal drugs, antibiotics, lipid-lowering drugs, or other gastrointestinal motility medications within the past 3 months;
* Subjects using other medications that can affect blood glucose in the past 3 months
* Subjects with consumption of other probiotic or prebiotic products in the past 3 months before secreening
* Subjects with lactose intolerance, known or suspected allergy to probiotics used in experiments, history of drug allergies or allergic diseases
* Subjects with weight fluctuations ≥ 5kg in the past 3 months or planning to take medication to control weight during the study period
* Subjects with history of mental illness or epilepsy, or taking antidepressant medications
* Subjects with history of alcohol abuse (for men, alcohol consumption exceeding 40 grams per day and for women, exceeding 20 grams per day)
* Subjects have participated in any other clinical study in the past 3 months

Where this trial is running

Beijing, Beijing Municipality

• Beijing Chao-yang Hospital, Capital Medical University — Beijing, Beijing Municipality, China (RECRUITING)

Study contacts

• Principal investigator: Guang Wang, MD — Beijing Chao Yang Hospital
• Study coordinator: Jia Liu, MD

Conditions: Type 2 Diabetes